Stock DVLA PT DARYA-VARIA LABORATORIA TBK
Add to a list
To use this feature you must be a member
Log inSign up

Financials PT Darya-Varia Laboratoria Tbk

Equities

DVLA

ID1000117203

Pharmaceuticals

End-of-day quote INDONESIA S.E.
Other stock markets
 06:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
1,545 IDR +0.98% Intraday chart for PT Darya-Varia Laboratoria Tbk +8.04% -7.21%
Apr. 29 PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 22 PT Darya-Varia Laboratoria Tbk Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 2,164,935 2,515,665 2,710,400 3,080,000 2,654,400 1,864,800
Enterprise Value (EV) 1 1,858,819 2,176,617 2,446,076 2,519,685 2,299,267 1,626,231
P/E ratio 10.8 x 11.3 x 16.7 x 21 x 17.8 x 12.7 x
Yield 5.52% 4.76% 4.55% 4.15% 5.02% -
Capitalization / Revenue 1.27 x 1.39 x 1.48 x 1.62 x 1.38 x 0.99 x
EV / Revenue 1.09 x 1.2 x 1.34 x 1.33 x 1.2 x 0.86 x
EV / EBITDA 6.03 x 6.08 x 9.24 x 10 x 9.25 x 6.57 x
EV / FCF -58.7 x 13.3 x 50.3 x 8.26 x -19.1 x -203 x
FCF Yield -1.7% 7.54% 1.99% 12.1% -5.23% -0.49%
Price to Book 1.8 x 1.93 x 2.04 x 2.23 x 1.89 x 1.33 x
Nbr of stocks (in thousands) 1,115,946 1,118,073 1,120,000 1,120,000 1,120,000 1,120,000
Reference price 2 1,940 2,250 2,420 2,750 2,370 1,665
Announcement Date 3/28/19 4/1/20 5/24/21 4/21/22 3/31/23 3/22/24
1IDR in Million2IDR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 1,699,657 1,813,020 1,829,700 1,900,894 1,917,041 1,890,888
EBITDA 1 308,345 358,027 264,612 251,421 248,677 247,360
EBIT 1 258,597 304,096 208,503 195,702 189,966 186,186
Operating Margin 15.21% 16.77% 11.4% 10.3% 9.91% 9.85%
Earnings before Tax (EBT) 1 272,844 301,250 214,069 211,794 201,073 191,638
Net income 1 200,652 221,783 162,073 146,726 149,375 146,336
Net margin 11.81% 12.23% 8.86% 7.72% 7.79% 7.74%
EPS 2 179.8 198.2 144.7 131.0 133.4 130.7
Free Cash Flow 1 -31,684 164,033 48,670 305,182 -120,339 -7,999
FCF margin -1.86% 9.05% 2.66% 16.05% -6.28% -0.42%
FCF Conversion (EBITDA) - 45.82% 18.39% 121.38% - -
FCF Conversion (Net income) - 73.96% 30.03% 208% - -
Dividend per Share 2 107.0 107.0 110.0 114.0 119.0 -
Announcement Date 3/28/19 4/1/20 5/24/21 4/21/22 3/31/23 3/22/24
1IDR in Million2IDR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 306,117 339,047 264,324 560,315 355,133 238,569
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -31,684 164,033 48,670 305,182 -120,339 -7,999
ROE (net income / shareholders' equity) 17.3% 17.7% 12.3% 10.8% 10.7% 10.4%
ROA (Net income/ Total Assets) 9.73% 10.8% 6.83% 6.01% 5.8% 5.74%
Assets 1 2,063,174 2,049,563 2,373,409 2,442,740 2,574,189 2,547,373
Book Value Per Share 2 1,076 1,167 1,184 1,233 1,253 1,254
Cash Flow per Share 2 274.0 303.0 237.0 521.0 319.0 214.0
Capex 1 45,488 58,955 62,807 84,944 58,185 97,916
Capex / Sales 2.68% 3.25% 3.43% 4.47% 3.04% 5.18%
Announcement Date 3/28/19 4/1/20 5/24/21 4/21/22 3/31/23 3/22/24
1IDR in Million2IDR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PT DARYA-VARIA LABORATORIA TBK Stock PT Darya-Varia Laboratoria Tbk
-7.21% 108M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.65% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DVLA Stock
  4. Financials PT Darya-Varia Laboratoria Tbk